Johan Sebregts
Direktor/Vorstandsmitglied bei River Biomedics B V I.O.
Profil
Johan Sebregts has worked as a Director at Segestio BV since 2012 and currently holds a position as a Non-Executive Director at River Biomedics B V I.O.
Aktive Positionen von Johan Sebregts
| Unternehmen | Position | Beginn |
|---|---|---|
Segestio BV
 Segestio BV Investment ManagersFinance Segestio BV is an independent private equity firm with its headquarters in Vlissingen, the Netherlands. It was founded in 2012. | Private Equity Investor | 01.10.2012 |
River Biomedics B V I.O.
 River Biomedics B V I.O. Medical SpecialtiesHealth Technology River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Segestio BV
Segestio BV Investment ManagersFinance Segestio BV is an independent private equity firm with its headquarters in Vlissingen, the Netherlands. It was founded in 2012. | Finance |
River Biomedics B V I.O.
River Biomedics B V I.O. Medical SpecialtiesHealth Technology River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper. | Health Technology |
